SGLT2-Inhibition: Ein wirksames Therapieprinzip des Diabetes mellitus?

Zusammenfassung

Seit Ende 2012 steht in Deutschland eine neue Substanzklasse zur Therapie des Typ 2 Diabetes zur Verfügung. Das Wirkprinzip ist neu und beruht auf einer Modulation der Glukoserückresorption im Harn durch Inhibition so genannter Sodium Glucose Linked Transporter (SGLT). Dadurch wird eine therapeutische Glukosurie induziert. Dies ist ein für den Arzt ungewohnter Behandlungsansatz, der die Niere als Ort der Glukoseregulation in den therapeutischen Mittelpunkt stellt. Daher sind eine nähere Betrachtung der hierfür verantwortlichen renalen Mechanismen sowie eine Darstellung der Vor- und Nachteile dieser Medikamentengruppe sinnvoll.

Abstract

Since end of 2012 a new therapeutical approach for the treatment of type 2 diabetes is available in Germany. It relies on the modulation of glucose re-absorption in the kidney by inhibition of so called Sodium Glucose Linked Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the kidney in the centre of therapeutical approach of glucose regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying renal mechanisms and to present the advantages and disadvantages of this new therapeutic class.

Schlüsselwörter

Blutdrucksenkung - Diabetes mellitus Typ 2 - Gewichtsreduktion - Glukosurie - medikamentöse Therapie - Sodium Glucose Linked Transporter (SGLT)

Keywords

blood pressure - type 2 diabetes - weight reduction - glucosuria - drug therapy - Sodium Glucose Linked Transporter (SGLT)

• Literatur:

• 1 Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012; 46: 590-598
• 2 Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233
• 3 Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 1981; 241: F322-F332
• 4 Bergman H, Dury DR. The relationship of kidney function to the glucose utilization of the extra abdominal tissues. Am J Physiol 1938; 124: 279-284
• 5 Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031
• 6 Calado J, Sznajer Y, Metzger D et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008; 23: 3874-3879
• 7 Devenny JJ, Godonis HE, Harvey SJ et al. Weight loss induced by chronic dapagliflozin treatment Is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity 2012; 20: 1645-1652
• 8 Devineni D, Morrow L, Hompesch M et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14: 539-545
• 9 Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224
• 10 Gerich JE. Role of the kidney in normal glucose homeostasis and in hyperglycemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136-142
• 11 Gerich JE. Physiology of glucosehomeostasis. Diabetes Obes Metab 2000; 2: 345-350
• 12 Ghosh RK, Ghosh SM, Chawla S et al. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 2012; 52: 457-463
• 13 Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90
• 14 Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209
• 15 Henry RR, Murray AV, Marmolejo MH et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-456
• 16 Hussey EK, Clark RV, Amin DM et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozinetabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010; 50: 623-635
• 17 Komoroski B, Vachharajani N, Feng Y et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519
• 18 Liday C. Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. Pharmacotherapy 2011; 31 (12) 37S-43S
• 19 Lin YY, Hsu CW, Sheu WH et al. Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia. Yonsei Med J 2010; 51: 367-374
• 20 Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; 79: 1-S6
• 21 Meyer C, Dostou JM, Welle SL et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002; 282: E419-E427
• 22 Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393
• 23 Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022
• 24 Ptaszynska A, Johnsson KM, Apanovitch AM et al. Safety of Dapagliflozin in Clinical Trials for T2DM. Diabetes 2012; 61 (Suppl. 01) 1011-P
• 25 Rosenstock J, Aggarwal N, Polidori D et al. Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238
• 26 Schwartz SL, Akinlade B, Klasen S et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011; 13: 1219-1227
• 27 Strojek K, Yoon KH, Hruba V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938
• 28 Stumvoll M, Meyer C, Mitrakou A et al. Renal glucose production and utilization: new aspects in humans. Diabetologia 1997; 40: 749-757
• 29 Stumvoll M, Meyer C, Perriello G et al. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 1998; 274: E817-826
• 30 Wilding JPH, Norwood P, T’joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiv­ing high doses of insulin plus insulin sensitizers: applicability of a novel insulin-dependent treatment. Diabetes Care 2009; 32: 1656-1662
• 31 Wilding JP, Woo VC, Rohwedder K et al. Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetes 2012; 61 (Suppl. (Suppl. 01) ) 1042-P
• 32 Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43
• 33 Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-794
• 34 Zhang L, Feng Y, List J et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516